Review of Vinflunine Data and Ongoing Developments in Urothelial Carcinoma
Overview of Registration Trials Data in Urothelial Carcinoma In total, 450 patients were treated in two phase II trials and one phase III trial that together formed the basis for the registration of vinflunine monotherapy in urothelial carcinoma patients after failure of platinum-based therapy (see Table 1).1–3 Similar data were reported in the two phase […]
Potential Role of Vinflunine in Two-tiered Treatment Strategies – Perioperative and Maintenance Therapy
The potential role of vinflunine in sequential treatment strategies for urothelial carcinoma, in both the perioperative setting and maintenance therapy, will be highlighted below. Rationale for Perioperative Systematic Therapy in Bladder Cancer The natural history and evolution of urothelial carcinoma suggests that the study of perioperative systemic therapy may yield benefits (see Table 1),1–9 because […]
First-line Systemic Therapy in Patients Ineligible (‘Unfit’) to Receive a Cisplatin-based Regimen – Which Patients? What Needs?
Standard Chemotherapy in ‘Fit’ Bladder Cancer Patients First-line treatment options in ‘fit’ bladder cancer patients who are able to receive platinum-based therapy include GC, paclitaxel/gemcitabine/cisplatin (PGC), methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) with or without granulocyte colony-stimulating factor (G-CSF), or high-dose (HD)-MVAC with G-CSF. The highest level of evidence and grade of recommendation is available […]
First-line Systemic Therapy in Patients Ineligible (‘Unfit’) to Receive a Cisplatin-based Regimen – Literature Review, Recommendations and Potential Use of Vinflunine in Combination or as Monotherapy
First-line Treatment of Unfit Bladder Cancer Patients – An Overview In the first-line setting treatment of unfit bladder cancer patients, a long list of small phase I, II and III trials investigating various combinations of chemotherapy regimens is available (see Table 1). Most data are on gemcitabine-based combinations, such as GCa, which is probably the […]
After Failure of Prior Chemotherapy – Cytotoxics, Targeted Agents, Immunomodulation – Current Available Data and Potential Synergistic Combinations with Vinflunine
An overview of evidence on use and development of cytotoxic and targeted agents in the second-line setting after failure of a platinum-based regimen will be presented below. Additional considerations on the possible role of immunotherapy in bladder cancer are also discussed. Combinations of vinflunine with therapeutic agents that are already in use in bladder cancer […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!